In a study conducted at the University of Pittsburgh Cancer Institute (UPCI), a novel dendritic-cell based vaccine in combination with poly-ICLC demonstrated safety, immune-reactivity, as well as efficacy in patients with recurrent malignant gliomas.

UPCI researchers presented their findings at the ASCO annual meeting in Chicago.

Watch Hideho Okada, MD, PhD, co-leader, Brain Tumor Program, UPCI, and associate professor of neurological surgery, Surgery and Immunology, University of Pittsburgh School of Medicine,  and Pawel Kalinski, MD, PhD, director of research, Division of Surgical Oncology, UPCI, and professor of surgery, University of Pittsburgh School of Medicine, discuss the oral presentation: